<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306900</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-030-002</org_study_id>
    <nct_id>NCT04306900</nct_id>
  </id_info>
  <brief_title>TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers</brief_title>
  <official_title>Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trishula Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Trishula Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39&#xD;
      enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP)&#xD;
      and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and&#xD;
      promote anti-tumor immune response.&#xD;
&#xD;
      This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and&#xD;
      anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard&#xD;
      chemotherapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of study subjects experiencing adverse events (AEs), dose-limiting toxicities, and serious adverse events (SAEs). Safety profile will be assessed through laboratory evaluations, vital signs, and physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>ORR is defined as the proportion of subjects with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>DoR will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>PFS is measured from documentation of progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Cycles 1-4 (each cycle is 21-28 days)</time_frame>
    <description>Serum concentrations of TTX-030 will be tabulated</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Combo 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab plus mFOLFOX6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab plus docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus mFOLFOX6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab (selected tumors evaluated in expansion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus nab-paclitaxel + gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budigalimab plus mFOLFOX6</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, budigalimab and mFOLFOX6</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, budigalimab and docetaxel</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030 and mFOLFOX6</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030 and budigalimab</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, budigalimab, nab-paclitaxel and gemcitabine</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030 and pembrolizumab</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, nab-paclitaxel and gemcitabine</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Budigalimab and mFOLFOX6</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older, is willing and able to provide informed consent&#xD;
&#xD;
          2. Histologically confirmed diagnosis of unresectable or metastatic solid tumor&#xD;
             malignancy in selected tumor types&#xD;
&#xD;
          3. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          4. ECOG performance status of 0-1&#xD;
&#xD;
        Abbreviated Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy or hypersensitivity to study treatment components. Patients with a&#xD;
             history of severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          2. Use of investigational agent within 28 days prior to the first dose of study treatment&#xD;
             and throughout the study&#xD;
&#xD;
          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          4. History of severe autoimmune disease&#xD;
&#xD;
          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trishula Therapeutics, Inc.</last_name>
    <phone>+1 888-480-0554</phone>
    <email>clinicaltrials@trishulatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, RN</last_name>
      <phone>480-323-1791</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center Clinical Trials Office</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Zhang</last_name>
      <phone>626-218-0867</phone>
      <email>tizhang@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Martinez</last_name>
    </contact>
    <contact_backup>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Wendel, RN-BSN, CCRP</last_name>
      <phone>310-967-4339</phone>
      <email>cancer.trial.info@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-633-8400</phone>
      <phone_ext>16045</phone_ext>
      <email>lyonemoto@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive CC, UCI</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>General Contact</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Turrell, CCRP</last_name>
      <phone>916-734-3089</phone>
      <email>ceturrell@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reisy Guedes, BS, CRC</last_name>
      <phone>305-243-8807</phone>
      <email>rxg957@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center PL</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjit Nirmalanandhan</last_name>
      <phone>352-547-1958</phone>
      <email>sanjit.nirmalanandhan@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health UF Health Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Donaldson</last_name>
      <phone>321-841-9821</phone>
      <email>karin.donaldson@orlandohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health - John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Quidley, MHA, ACRP-CP</last_name>
      <phone>706-229-7439</phone>
      <email>kquidley@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Recruitment</last_name>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Department</last_name>
      <phone>502-629-2500</phone>
      <email>MISC-NCIResearch@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Jerdonek</last_name>
      <phone>504-842-3929</phone>
      <email>sharon.jerdonek@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Center Oncology Hematology West P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays, M.A. CCRC</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Sanjay Goel, MD</last_name>
      <phone>718-405-8404</phone>
      <email>sgoel@montefiore.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services</last_name>
      <phone>800-641-2422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Sholl</last_name>
      <phone>419-383-4553</phone>
      <email>jill.sholl@utoledo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Obarski</last_name>
      <phone>419-383-6972</phone>
      <email>jessica.obarski@utoledo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma-Health Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane W McClain</last_name>
      <phone>864-455-3781</phone>
      <email>jmcclain@ghs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center and Research Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <phone>901-683-0055</phone>
      <email>afletcher@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Line</last_name>
      <phone>615-329-7478</phone>
      <email>Cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-580-9521</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunstman Cancer Intitute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Conway</last_name>
      <phone>801-587-4021</phone>
      <email>hannah.conway@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD</last_name>
      <phone>703-280-5390</phone>
      <email>alexander.spira@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>General Cancer Center Info</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Seogu</city>
        <state>Busan</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Yong Oh</last_name>
      <phone>+82-51-240-2808</phone>
      <email>drosy@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Ilsandong-gu</city>
        <state>Goyang-si, Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Cha</last_name>
      <phone>+82-31-920-1668</phone>
      <email>yongjuncha@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seongnam-si Bundan-gu</city>
        <state>Kyunggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Wook Lee</last_name>
      <phone>+82-31-787-7037</phone>
      <email>imdoctor@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Tae Kim</last_name>
      <phone>+82-2-3410-0297</phone>
      <email>seungtae1.kim@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Joon Shin</last_name>
      <phone>+ 82-2-2228-8138</phone>
      <email>SSJ338@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang</last_name>
      <phone>+82-2-3010-8771</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric (gastroesophageal cancer)</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>CD39</keyword>
  <keyword>Adenosine Pathway</keyword>
  <keyword>Immunotherapy Immuno-oncology</keyword>
  <keyword>PD-1 Checkpoint Inhibitor</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Budigalimab</keyword>
  <keyword>ABBV-181</keyword>
  <keyword>TTX-030</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Urothelial cell cancer</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

